Global sales for the cervical and lumbar disc replacement devices were $23.4 million, according to a news release. Resources associated with the discs will be allocated to “more profitable growth opportunities.”
Orthofix will still fulfill requirements related to post-market surveillance activities and completion of an Investigational Device Exemption study in the U.S.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
